Goldman Sachs has put together a list of stocks with strong potential for return on equity this year and low price-to-book ratios.

Second-quarter earnings season winds down next week with just five S&P 500 constituents slated to report.

Jim Cramer explains these tortuous, trade-related rotations. He says it's best to catch your next buying opportunity on the way down, not on the chase up.

The downgrade to BB from BBB- comes as the drugmaker continues to face challenges such as a competitive generic drug market in the U.S.

The 'winning formula' for this year focuses on growth, size and foreign stocks, Jefferies says.

The struggling drug company needs to take some major steps to address its massive debt load, analysts say.

The job cuts are part of the Petach Tikva, Israel-based drugmaker's restructuring efforts aimed at lowering its total cost base by $3 billion by the end of 2019.

After a shortened trading week light on volume, the S&P 500 is losing some steam. But Fundstrat says index uptrends 'remain intact' moving toward the New Year.

The Israel-based drugmaker on Nov. 27 unveiled a a new organizational structure and said it plans to announce a detailed restructuring plan next month.

Apple is asking assemblers to put together 220 million iPhones this year, Bloomberg reported, a tally that largely matches 2021 levels.

Electric-truck manufacturer Nikola, like the broad vehicle industry, has been struggling with supply-chain issues.

DNA-sequencing leader Illumina swung to a loss in Q2 2022. Contributions from Grail didn't help.